The current valuation score of Galapagos NV is 8.15, ranking 60 out of 385 in the Biotechnology & Medical Research industry. Its current P/E ratio is 4.32, which is 514.08% below the recent high of 26.51 and 553.28% above the recent low of -19.57.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.